Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program

Redx to receive $10 million upfront; potential for up to $870 million in development, regulatory and sales milestone payments in addition to royalties on future net sales Preclinical program expands Jazz’s pipeline of targeted oncology therapies DUBLIN and ALDERLEY PARK, United Kingdom,…